We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Malin Corp plc (MLC) EUR0.001

Sell:€5.75 Buy:€5.80 Change: €0.05 (0.86%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Change: €0.05 (0.86%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Change: €0.05 (0.86%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Malin Corporation PLC is focused on investing in life sciences companies. The Company’s assets give investors access to life sciences businesses with exposure across diverse modalities, therapeutic areas and geographies. Its business includes Poseida, Viamet, Xenex, CG Oncology, Wren, KNOW Bio and Artizan. Poseida is a clinical-stage biopharmaceutical company building a pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of hematological malignancies, including multiple myeloma, and solid tumours, like prostate cancer. It is also developing two CAR-T therapies: autologous and allogeneic. Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its non-mercury, full-spectrum disinfection LightStrike Germ-Zapping robots. CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder-saving therapeutics for patients with bladder cancer.

Contact details

The Lennox Building
50 Richmond Street South
D02 FK02
+353 (1) 9015700

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€109.07 million
Shares in issue:
18.97 million
Life Sciences Tools & Services

Key personnel

  • Neil McLoughlin
    General Counsel, Company Secretary
  • Fiona Dunlevy
    Executive Director
  • David Dobrosky
    Senior Analyst
  • Peter Schwartzman
    Member of Senior Management Team

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.